GlassScriptPhysician profile
Kimberly Bernard
NPI 1619498417
$3,289.73
in general payments reported to CMS, 2019-2025
28 companies · $567 in 2025
The $567 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $767 · 2023: $1,486 · 2024: $353 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Travel and Lodging: $842 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.10 |
| Travel and Lodging | $841.69 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,068.87 | 2023 | Altis |
| Bayer Healthcare Pharmaceuticals INC. | $268.77 | 2021-2025 | |
| Abbvie INC. | $218.49 | 2022-2024 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $197.12 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $182.84 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $174.30 | 2022-2024 | |
| Coopersurgical, INC. | $170.08 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Biotissue Holdings INC. | $146.33 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $94.54 | 2023-2025 | Myfembree |
| Millicent US INC | $79.04 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $74.78 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $70.87 | 2021-2024 | |
| Organon LLC | $58.36 | 2022-2024 | |
| Agile Therapeutics, INC. | $55.98 | 2021-2022 | |
| Scynexis, INC. | $55.23 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.09 | 2022-2023 | Seglentis |
| Davol INC. | $49.58 | 2025 | Arista |
| Exeltis, USA INC. | $45.86 | 2024-2025 | Slynd |
| Ethicon US, LLC | $44.81 | 2022-2024 | Vistaseal |
| Biogen, INC. | $36.39 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $27.35 | 2023 | Accrufer |
| Mission Pharmacal Company | $22.61 | 2023 | Citranatal |
| Viiv Healthcare Company | $21.19 | 2024 | Apretude |
| Cumberland Pharmaceuticals, INC. | $19.35 | 2021 | |
| Optumhealth Care Solutions, LLC | $18.61 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Evofem Biosciences, INC. | $15.19 | 2022 | |
| Lupin INC. | $14.50 | 2021 | |
| Channel Medsystems, INC. | $7.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.